AC0176
Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
BROOKLYN, N.Y. - Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on art...
- 3 years ago
